No Data
No Data
PDS Biotechnology Corporation Announces Three Abstracts Accepted for ASCO 2025 on Versamune HPV Immunotherapy
Express News | PDS Biotechnology Corp : B. Riley Cuts Target Price to $5 From $7
Express News | PDS Biotech To Present At American Association of Immunologists' IMMUNOLOGY2025 Annual Meeting May 3-7
PDS Biotech Announces PDS01ADC Clinical Data to Be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
New Analyst Forecast: $PDSB Given 'Buy' Rating
A. G. P. Maintains PDS Biotechnology(PDSB.US) With Buy Rating, Maintains Target Price $4.5